论文部分内容阅读
目的:观察甘精胰岛素联合二甲双胍治疗2型糖尿病的疗效和安全性。方法:80例口服降糖药控制不佳的2型糖尿病门诊患者,随机分为观察组和对照组。观察组皮下注射甘精胰岛素,qd,并予以二甲双胍500mg,po bid;对照组皮下注射预混胰岛素治疗,bid,两组均连用12周。观察两组患者治疗前后空腹血糖(FBG)、餐后2h血糖(2hPG)和糖化血红蛋白(HbAlc)水平,检查肝、肾功能,比较两组患者治疗后FBG、2 h PG和HbAlc的达标率,并记录患者低血糖事件的发生率。结果:两组患者治疗12周后FBG、2 hPG和HbAlc较治疗前明显下降(P<0.01和P<0.05),观察组患者2 hPG和HbA1C下降幅度较对照组更明显(P<0.05);观察组患者FBG、2 hPG和HbAlc的达标率明显高于对照组(P<0.01),观察组患者低血糖的发生率明显低于对照组(P<0.05)。两组患者治疗期间肝、肾功能均无异常改变。结论:甘精胰岛素联合二甲双胍治疗2型糖尿病能更好的降低患者血糖和糖化血红蛋白水平,血糖及糖化血红蛋白达标率较高,低血糖发生率低。
Objective: To observe the efficacy and safety of insulin glargine combined with metformin in the treatment of type 2 diabetes mellitus. Methods: Eighty outpatients with type 2 diabetes with poorly controlled oral hypoglycemic agents were randomly divided into observation group and control group. The observation group was subcutaneously injected with insulin glargine qd, and metformin 500mg, po bid; control group subcutaneous injection of premixed insulin treatment, bid, both for 12 weeks. The fasting blood glucose (FBG), postprandial 2h blood glucose (2hPG) and HbAlc levels were observed before and after treatment in both groups to check the liver and kidney function. The compliance rates of FBG, 2h PG and HbAlc after treatment were compared between the two groups. And record the incidence of hypoglycemia in patients. Results: The levels of FBG, 2 hPG and HbAlc in two groups were significantly decreased (P <0.01 and P <0.05 respectively) after treatment for 12 weeks, while the decrease of 2 hPG and HbA1C in observation group was more obvious than that of the control group (P <0.05). The compliance rates of FBG, 2 hPG and HbAlc in observation group were significantly higher than those in control group (P <0.01). The incidence of hypoglycemia in observation group was significantly lower than that in control group (P <0.05). Two groups of patients with liver and kidney function during the treatment without abnormal changes. Conclusion: Glargine and metformin in treatment of type 2 diabetes patients can better reduce the level of blood glucose and glycosylated hemoglobin, high blood glucose and glycosylated hemoglobin compliance rate, low incidence of hypoglycemia.